Abstract
Estrogens are known to be important in breast cancer growth in both pre- and post-menopausal women. Although circulating estrogen concentrations are very low after menopause, peripheral tissues generate sufficient concentrations to stimulate tumor growth. As aromatase is the rate-limiting enzyme in estrogen biosynthesis, inhibitors of this enzyme represent effective targeted therapy for breast cancer. Three compounds are now FDA approved and have become the first-choice endocrine drugs for postmenopausal breast cancer patients, since they are associated with superior activity and better general tolerability when compared with the estrogen receptor modulator tamoxifen. Nevertheless, some questions concerning the use of aromatase inhibitors for the treatment of breast cancer still need to be addressed, mainly related to their side-effects and the development of resistance, making research in this field still appealing. Many research groups, including our own, are still dealing with the search of new compounds that possess aromatase inhibitory properties. In this review an update of the latest achievements in the field of nonsteroidal aromatase inhibitors will be given.
Keywords: Anticancer, aromatase inhibitors, breast cancer, chemopreventive, cytochrome P450, CYP19, drug discovery, endocrine therapy, estrogens, flavonoids, natural products, nonsteroidal.
Anti-Cancer Agents in Medicinal Chemistry
Title:Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update
Volume: 14 Issue: 1
Author(s): Silvia Gobbi, Angela Rampa, Federica Belluti and Alessandra Bisi
Affiliation:
Keywords: Anticancer, aromatase inhibitors, breast cancer, chemopreventive, cytochrome P450, CYP19, drug discovery, endocrine therapy, estrogens, flavonoids, natural products, nonsteroidal.
Abstract: Estrogens are known to be important in breast cancer growth in both pre- and post-menopausal women. Although circulating estrogen concentrations are very low after menopause, peripheral tissues generate sufficient concentrations to stimulate tumor growth. As aromatase is the rate-limiting enzyme in estrogen biosynthesis, inhibitors of this enzyme represent effective targeted therapy for breast cancer. Three compounds are now FDA approved and have become the first-choice endocrine drugs for postmenopausal breast cancer patients, since they are associated with superior activity and better general tolerability when compared with the estrogen receptor modulator tamoxifen. Nevertheless, some questions concerning the use of aromatase inhibitors for the treatment of breast cancer still need to be addressed, mainly related to their side-effects and the development of resistance, making research in this field still appealing. Many research groups, including our own, are still dealing with the search of new compounds that possess aromatase inhibitory properties. In this review an update of the latest achievements in the field of nonsteroidal aromatase inhibitors will be given.
Export Options
About this article
Cite this article as:
Gobbi Silvia, Rampa Angela, Belluti Federica and Bisi Alessandra, Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990306
DOI https://dx.doi.org/10.2174/18715206113139990306 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens
Recent Patents on Anti-Cancer Drug Discovery Role of Sigma Receptors in Methamphetamine-Induced Neurotoxicity
Current Neuropharmacology A Review of Eugenol-based Nanomedicine: Recent Advancements
Current Bioactive Compounds Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Exploring Therapeutic Potential of Nanocarrier Systems Against Breast Cancer
Pharmaceutical Nanotechnology Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research Clinical Management of Infectious Diarrhea
Reviews on Recent Clinical Trials Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Editorial [Hot Topic: Tyrosine Kinase Inhibitors in Cancer Therapy (Guest Editor: S. Eckhardt)]
Anti-Cancer Agents in Medicinal Chemistry Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Mesoporous Materials Used in Medicine and Environmental Applications
Current Topics in Medicinal Chemistry Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics Th1-mediated Pathology in Mouse Models of Human Disease is Ameliorated by Concurrent Th2 Responses to Parasite Antigens
Current Topics in Medicinal Chemistry The Effect of Melatonin on Superoxide Dismutase and Glutathione Peroxidase Activity, and Malondialdehyde Levels in the Targeted and the Non-targeted Lung and Heart Tissues after Irradiation in Xenograft Mice Colon Cancer
Current Molecular Pharmacology